NYSE · Medical - Devices
AVNS (AVNS) Stock
$24.99
+0.04%
NYSE: AVNS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
AVNS: What does Argus have to say about AVNS?
Argus Research · Jul 15, 2026
Avanos, American Industrial Get Regulatory Approval for Merger
MT Newswires · Jul 2, 2026
Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
PR Newswire · Jul 2, 2026
Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last?
Zacks · Jun 29, 2026
Reasons to Retain Avanos Medical Stock in Your Portfolio for Now
Zacks · Jun 24, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.28%
Institutions Held92.74%
Institutions Float Held95.89%
Peer Comparison
About AVNS
AVNS is led by CEO David C. Pacitti, employs 2,227 people, headquartered in US, publicly traded since 2014.
AVNS stock trades at $24.99 with a market capitalization of $1.17B. The stock is valued at a price-to-earnings (P/E) ratio of 19.96, price-to-book of 1.49, price-to-sales of 1.63. Over the past 52 weeks the stock has ranged between $9.30 and $25.49, and currently trades 2.0% below its 52-week high.
On profitability, AVNS generates a return on equity (ROE) of -9.18%, return on capital employed of -7.97%, an operating margin of -7.92%, a net profit margin of -9.69%.